Advances in autophagy modulation of natural products in cervical cancer

Tao, Tao; Zhang, Ping; Zeng, Zhi Fan; Wang, Min

doi:10.1016/j.jep.2023.116575

Cited by 8 publications

(5 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, studies have confirmed that the occurrence and development of cervical cancer are closely related to apoptosis and autophagy [ 28 ]. Autophagy is a catabolic pathway through which some cellular components are transported to lysosomes by autophagosomes [ 29 ].…”

Section: Resultsmentioning

confidence: 96%

Design, Synthesis, and Antitumor Activity of Isoliquiritigenin Amino Acid Ester Derivatives

Liu,

et al. 2024

Molecules

View full text Add to dashboard Cite

Isoliquiritigenin (ISL) is a chalcone that has shown great potential in the treatment of cancer. However, its relatively weak activity and low water solubility limit its clinical application. In this study, we designed and synthesized 21 amino acid ester derivatives of ISL and characterized the compounds using 1H NMR and 13C NMR. Among them, compound 9 (IC50 = 14.36 μM) had a better inhibitory effect on human cervical cancer (Hela) than ISL (IC50 = 126.5 μM), and it was superior to the positive drug 5-FU (IC50 = 33.59 μM). The mechanism of the action experiment showed that compound 9 could induce Hela cell apoptosis and autophagy through the PI3K/Akt/mTOR pathway.

show abstract

Section: Resultsmentioning

confidence: 96%

Design, Synthesis, and Antitumor Activity of Isoliquiritigenin Amino Acid Ester Derivatives

Liu,

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…Therefore, we speculate that EZH1 may play a role in the development of HCC by regulating autophagy. In addition, recent studies have shown that autophagy was associated with drug resistance in anti-tumor therapy, such as in cervical cancer [21]. And autophagy inhibitors were found to have a surprisingly effective therapeutic effect when combined with molecular targeted or chemotherapeutic drugs in HCC [22].…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues

Chen,

Li,

Huang

et al. 2024

JGLD

View full text Add to dashboard Cite

Background and Aims: The incidence and mortality of hepatocellular carcinoma (HCC) are increasing. It is urgent to develop more effective HCC biomarkers for diagnosis and treatment. This project intends to verify the expression of enhancer of zeste 1 polycomb repressive complex 2 subunit (EZH1) and its mechanism in HCC. Methods: This study integrates global microarray and high-throughput sequencing datasets, combined with internal immunohistochemistry, to analyze the expression and prognostic value of EZH1 in HCC. Functional enrichment analysis was conducted to investigate transcriptional targets, which were achieved by intersecting HCC over-expressed genes, EZH1 co-expressed genes and putative transcriptional targets. The relationship between EZH1 and anticancer drugs was detected by drug sensitivity analysis. Results: In this study, 84 datasets from 40 platforms (3,926 HCC samples and 3,428 non-cancerous liver tissues) were included to show the high expression of EZH1 in HCC. Immunohistochemistry with 159 HCC samples and 62 non-HCC samples confirmed the high expression level. HCC patients with high EZH1 expression had worse survival prognoses. Gene ontology and Reactome analysis revealed that metabolism-related pathways, including autophagy, are critical for HCC. Interestingly, as one of the EZH1 potential transcriptional targets, autophagy-related 7 (ATG7) appeared in the above pathways. ATG7 was positively correlated with EZH1, upregulated in HCC, and mediated poor prognosis. Upregulation of EZH1 was found to be in contact with HCC anti-tumor drug resistance. Conclusions: The upregulation of EZH1 expression can promote the occurrence of HCC and lead to poor clinical progression and drug resistance; these effects may be mediated by regulating ATG7.

show abstract

“…Therefore, we speculate that EZH1 may play a role in the development of HCC by regulating autophagy. In addition, recent studies have shown that autophagy is associated with drug resistance in anti-tumor therapy, such as in cervical cancer (Tao et al 2023). And autophagy inhibitors were found to have a surprisingly effective therapeutic effect when combined with molecular targeted or chemotherapeutic drugs in HCC (Wu et al 2021).…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues

Chen

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose The incidence and mortality of hepatocellular carcinoma (HCC) are increasing. It is urgent to develop more effective HCC biomarkers for diagnosis and treatment. This project intends to explore the expression of the enhancer of zeste 1 polycomb repressive complex 2 subunit (EZH1) and its mechanism in HCC. Methods This study integrates global microarray and high-throughput sequencing datasets, combined with internal immunohistochemistry, to analyze the expression and prognostic value of EZH1 in HCC. Functional enrichment analysis was conducted to investigate transcriptional targets, which were achieved by intersecting HCC over-expressed genes and EZH1 co-expressed genes, putative transcriptional targets. The relationship between EZH1 and anticancer drugs was detected by drug sensitivity analysis. Results In this study, 84 datasets from 40 platforms (3926 HCC samples and 3428 non-cancerous liver tissues) were included to show the high expression of EZH1 in HCC. Immunohistochemistry with 159 HCC samples and 62 non-HCC samples confirmed a high expression level. HCC patients with high EZH1 expression had worse survival prognoses. GO and Reactome analysis revealed that metabolism-related pathways, including autophagy, are critical for HCC. Interestingly, as one of the EZH1 potential transcriptional targets, autophagy-related 7 (ATG7) appeared in the above pathways. ATG7 was positively correlated with EZH1, upregulated in HCC, and mediated poor prognosis. Upregulation of EZH1 was found to be in contact with HCC anti-tumor drug resistance. Conclusion The upregulation of EZH1 expression can promote the occurrence of HCC and lead to poor clinical progression and drug resistance, these effects may be mediated by regulating ATG7.

show abstract

Advances in autophagy modulation of natural products in cervical cancer

Cited by 8 publications

References 150 publications

Design, Synthesis, and Antitumor Activity of Isoliquiritigenin Amino Acid Ester Derivatives

Design, Synthesis, and Antitumor Activity of Isoliquiritigenin Amino Acid Ester Derivatives

Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues

Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues

Contact Info

Product

Resources

About